Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
101
datasets available to search
ShareScore release 0.9.0
Dataset results
101 results for “frontotemporal dementia”
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
ClinicalTrials.gov study NCT02372773. IPD Sharing: YES. Countries: 2. Publications: 27.
Oxytocin and Social Cognition in Frontotemporal Dementia
ClinicalTrials.gov study NCT01002300. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
ClinicalTrials.gov study NCT01626378. IPD Sharing: Not stated. Countries: 12. Publications: 1.
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
ClinicalTrials.gov study NCT03225144. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
ClinicalTrials.gov study NCT00613119. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
ClinicalTrials.gov study NCT01925196. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
ClinicalTrials.gov study NCT01353430. IPD Sharing: Not stated. Countries: 1. Publications: 34.
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
ClinicalTrials.gov study NCT03636204. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Direct Current Brain Polarization in Frontotemporal Dementia
ClinicalTrials.gov study NCT00077896. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients
ClinicalTrials.gov study NCT00200538. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
ClinicalTrials.gov study NCT02149160. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized
ClinicalTrials.gov study NCT01403519. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Dopaminergic Therapy for Frontotemporal Dementia Patients
ClinicalTrials.gov study NCT04937452. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum
Open the record for dataset details and reuse information.
Supplementary material for: Neural effects of oxytocin and mimicry in frontotemporal dementia: A randomized cross-over study
Open the record for dataset details and reuse information.
Data from: Longitudinal structural and metabolic changes in frontotemporal dementia
Open the record for dataset details and reuse information.
Supplementary material - measuring atrophy in the behavioral variant of frontotemporal dementia: a multicenter study
<p><span><span><span><span><span><span><span><span><span><span><span><b>Objective:</b> To test the hypothesis that accesible and reproducible measures of atrophy may have high clinical utility for the study of patients with the behavioral variant of frontotemporal dementia (bvFTD), we determined the diagnostic and prognostic value of six previously-validated visual atrophy scales (VAS) and the Magnetic Resonance Parkinsonism Index (MRPI).</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Methods:</b> We gathered data from 235 patients with bvFTD and 225 age- and MRI-matched healthy controls from three centers. One hundred twenty-one bvFTD participants had underlying frontotemporal lobar degeneration (bvFTD-FTLD) and nineteen did not have FTLD (bvFTD-noFTLD). Blinded clinicians applied VAS and the MRPI was calculated with a fully-automated approach. Cortical thickness and subcortical gray matter volumes were also calculated for comparison. We used linear mixed and Cox regression models to evaluate the ability of atrophy measures to predict clinical deterioration and survival.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Results: </b>The bvFTD atrophy score (sum of atrophy scores in orbitofrontal, anterior cingulate, anterior temporal, medial temporal lobe and frontal insula regions) was usefull to discriminate bvFTD-FTLD from healthy controls (AUROC=.930; 95%CI, .903 to .957) and bvFTD-FTLD from bvFTD-noFTLD (AUROC=.880; 95%CI, .787 to .972) and had similar accuracy than cortical thickness and subcortical gray matter volumes. MRPI was increased in patients with bvFTD with underlying 4R tauopathies. The bvFTD atrophy score was an independent predictor of clinical deterioration and survival in bvFTD.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Conclusions:</b> In bvFTD, the bvFTD atrophy score can increase the diagnostic certainty of underlying FTLD and predict disease progression. Moreover, the MRPI can identify bvFTD participants with an increased risk of underlying 4R tauopathies.</span></span></span></span></span></span></span></span></span></span></span></p>
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
ClinicalTrials.gov study NCT02245568. IPD Sharing: Not stated. Countries: 17. Publications: 0.
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
ClinicalTrials.gov study NCT01890343. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
ClinicalTrials.gov study NCT02862210. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.